N‐Acetylcysteine (NAC) in Young Marijuana Users: An Open‐Label Pilot Study
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
N-acetylcysteine produced positive results for cannabis use cessation and craving in past open-label and placebo-controlled trials among adolescents.
“a number of trials have evaluated N-acetylcysteine, a modulator of glutamatergic receptors, because of positive results for cannabis use cessation and subjective measures (craving) in past open-label and placebo-controlled trials among adolescents 68, 69.”
From Psychosocial and pharmacological interventions for the treatment of cannabis use disorder (2018) · cites this paper as [69]
The study’s results report reduced self-reported marijuana use and craving during NAC treatment. But its 24 participants were aged 18–21, and this was an open-label study without a control group. It did not establish cannabis cessation or provide placebo-controlled results. (LLM, conf=0.88)
Experimental — accuracy not yet measuredCB1 agonists, gabapentin, and N-acetylcysteine have been shown to produce improvements in some symptoms of CUD in single studies.
“Some drugs, such as CB1 agonists, gabapentin, and N-acetylcysteine, have been shown to produce improvements in some symptoms of CUD in single studies”
From Psychosocial and pharmacological interventions for the treatment of cannabis use disorder (2018) · cites this paper as [69]
The Results and discussion report reduced self-reported marijuana use and craving during NAC treatment in young people with cannabis dependence. The study was open-label and had no control group, so it cannot establish that NAC produced those improvements; it does not study CB1 agonists or gabapentin. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Glutamatergic substrates of drug addiction and alcoholism
Gass, J. T., & Olive, M. F. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.039 · Cited by 485 · see citing works
The Role of Cystine-Glutamate Exchange in Nicotine Dependence in Rats and Humans
Knackstedt, L. A., LaRowe, S., Mardikian, P., Malcolm, R., Upadhyaya, H., Hedden, S., Markou, A., & Kalivas, P. W. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.040 · Cited by 260 · see citing works
Self-citationSafety and Tolerability of N‐Acetylcysteine in Cocaine‐Dependent Individuals
LaRowe, S. D., Mardikian, P. N., Malcolm, R. J., Myrick, H., Kalivas, P. W., McFarland, K., Saladin, M. E., McRae‐Clark, A. L., & Brady, K. T. (2006) · American Journal on Addictions · doi:10.1080/10550490500419169 · Cited by 181 · see citing works
Self-citationDifferentiating New Marijuana Use From Residual Drug Excretion in Occasional Marijuana Users
Huestis, M. A., & Cone, E. J. (1998) · Journal of Analytical Toxicology · doi:10.1093/jat/22.6.445 · Cited by 158 · see citing works
Kau, K. S., Madayag, A., Mantsch, J. R., Grier, M. D., Abdulhameed, O., & Baker, D. L. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.010 · Cited by 113 · see citing works
Levin, F. R., McDowell, D., Evans, S. M., Nunes, E., Akerele, E., Donovan, S., & Vosburg, S. K. (2004) · The American Journal on Addictions · doi:10.1080/10550490490265280 · Cited by 113 · see citing works
Carpenter, K. M., McDowell, D., Brooks, D. J., Cheng, W. Y., & Levin, F. R. (2009) · The American Journal on Addictions · doi:10.1080/10550490802408936 · Cited by 89 · see citing works
Challenges in Quantifying Marijuana Use
Gray, K. M., Watson, N. L., & Christie, D. K. (2009) · American Journal on Addictions · doi:10.1080/10550490902772579 · Cited by 38 · see citing works
Self-citationAssessment of Cannabis Craving Using the Marijuana Craving Questionnaire
Heishman, S. J., & Singleton, E. G. (2006) · Humana Press eBooks · doi:10.1385/1-59259-999-0:209 · Cited by 31 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The chemistry and biological activities of N-acetylcysteine
Samuni, Y., Goldstein, S., Dean, O. M., & Berk, M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.016 · Cited by 876 · see citing works
Dean, O., Giorlando, F., & Berk, M. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100057 · Cited by 494 · see citing works
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463 · see citing works
Leeman, R. F., & Potenza, M. N. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2550-7 · Cited by 448 · see citing works
The promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434 · see citing works
Gray, K. M., Carpenter, M. J., Baker, N. L., DeSantis, S. M., Kryway, E., Hartwell, K. J., McRae-Clark, A. L., & Brady, K. T. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010055 · Cited by 306 · see citing works
Self-citationPharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156 · see citing works
Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies
Fadus, M. C., Squeglia, L. M., Valadez, E. A., Tomko, R. L., Bryant, B. E., & Gray, K. M. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1086-0 · Cited by 127 · see citing works
Self-citationSchmaal, L., Berk, L., Hulstijn, K. P., Cousijn, J., Wiers, R. W., & van den Brink, W. (2011) · European Addiction Research · doi:10.1159/000327682 · Cited by 93 · see citing works
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders
Bradlow, R. C. J., Berk, M., Kalivas, P. W., Back, S. E., & Kanaan, R. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00907-3 · Cited by 87 · see citing works
Pharmacological Treatment of Youth Substance Use Disorders
Squeglia, L. M., Fadus, M. C., McClure, E. A., Tomko, R. L., & Gray, K. M. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0009 · Cited by 79 · see citing works
Self-citationGlutamate transport: a new bench to bedside mechanism for treating drug abuse
Spencer, S., & Kalivas, P. W. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx050 · Cited by 71 · see citing works
Weinstein, A. M., Miller, H., Bluvstein, I., Rapoport, E., Schreiber, S., Bar-Hamburger, R., & Bloch, M. (2014) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.819362 · Cited by 53 · see citing works
Psychosocial and pharmacological interventions for the treatment of cannabis use disorder
Sabioni, P., & Le Foll, B. (2018) · F1000Research · doi:10.12688/f1000research.11191.1 · Cited by 37 · see citing works
- Authors
- Gray, K. M., Watson, N. L., Carpenter, M. J., & LaRowe, S. D.
- Affiliations
- Medical University of South Carolina (US)
- Venue
- The American Journal on Addictions
- Publisher
- Wiley
- Published
- 2010-02-16
- Volume
- 19
- Issue
- 2
- Pages
- 187-189
- ISSN
- 1055-0496 (ISSN-L)
- 1521-0391
- PMC
- PMC2826714
- OpenAlex
- W2102956593
- Cited by
- 109
- References
- 9
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 9 · 2021: 9 · 2020: 3 · 2019: 7 · 2018: 10 · 2017: 6 · 2016: 11 · 2015: 8 · 2014: 7 · 2013: 9 · 2012: 9
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal on Addictions (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (K23DA020482, R01DA026777, K12DA000357)
- National Center for Research Resources (M01 RR-01070, M01RR001070)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- N-acetylcysteine, cannabis use, cannabis users, young adults, glutathione S-transferase inhibition
- MeSH terms
- Acetylcysteine, Adolescent, Cannabinoids, Marijuana Abuse, Female, Humans, Male, Pilot Projects, Behavior, Addictive, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
